Zacks has reiterated their neutral rating on shares of Boston Scientific. Zacks currently has a $16 target price on the stock. Boston Scientific traded up 0.83 percent during mid-day trading on Friday, Feb. 6, hitting $14.57.
Exact Sciences and Mayo Clinic, based in Rochester, Minn., announced a five-year extension and expansion of their collaboration. The new agreement focuses on Exact Sciences’ relationship with Mayo Clinic gastroenterologist and co-inventor of Cologuard David Ahlquist, MD.
Interpace Diagnostics, a subsidiary of PFI, announced results from a study that found that PancraGen (previously known as PathFinderTG-Pancreas) is 90 percent accurate at predicting benign and malignant disease in patients with pancreatic cysts.
Physicians Endoscopy and four gastroenterologist partners officially opened the Greater Gaston Endoscopy Center in Gastonia, N.C.
Salix Pharmaceuticals‘ shares have risen 19.35 percent over the past four weeks, with an 4.66 percent increase within the past week, according to an Ashburn Daily report.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.
More articles on gastroenterology:
Boston Scientific profits down 19%, Cologuard comes to Kentuck, Sovaldi to go generic & more – 6 GI/endoscopy company key notes
Does physical health play a role in gastroenterologist burnout? 6 statistics
6 GI/endoscopy devices recently approved by the FDA
